Phio Pharmaceuticals Announces Podium Presentations on INTASYL siRNA Lead Product Candidates PH-762 and PH-894To be presented at 11th Annual Immunotherapy of Cancer (ITOC) Conference in Munich, Germany Marlborough, Massachusetts--(Newsfile Corp. - April 3,...
Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business UpdateContinues advancing clinical trial for INSTASYL siRNA lead product candidate PH-7623rd Cohort now fully enrolled in on-going clinical studyMarlborough, Massachusetts--(Newsfile...
American Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical's Clinical Research at 2025 Annual MeetingMarlborough, Massachusetts--(Newsfile Corp. - March 10, 2025) - Phio Pharmaceuticals Corp. (
NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics...
Phio Pharmaceuticals Announces Completion of Enrollment in Third Safety Cohort in PH-762 Phase 1b Dose-Escalation StudyMarlborough, Massachusetts--(Newsfile Corp. - March 5, 2025) - Phio Pharmaceuticals Corp. (
NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics...
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow SeriesMarlborough, Massachusetts--(Newsfile Corp. - February 26, 2025) - Phio Pharmaceuticals Corp. (
NASDAQ: PHIO) a clinical-stage biotechnology company developing therapeutics that...
Phio Pharmaceuticals Announces Appointment of David H. Deming to Board of DirectorsMarlborough, Massachusetts--(Newsfile Corp. - February 20, 2025) - Phio Pharmaceuticals Corp. (
NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics...
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow SeriesMarlborough, Massachusetts--(Newsfile Corp. - February 3, 2025) - Phio Pharmaceuticals Corp. (
NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics...
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow SeriesMarlborough, Massachusetts--(Newsfile Corp. - January 22, 2025) - Phio Pharmaceuticals Corp. (
NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics...
Phio Pharmaceuticals Announces Closing of $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesRaised approximately $12.08 million in gross proceeds since beginning of December 2024 Proceeds intended to be directed for development costs...
Phio Pharmaceuticals Announces $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMarlborough, Massachusetts--(Newsfile Corp. - January 16, 2025) - Phio Pharmaceuticals Corp. (
NASDAQ: PHIO), a clinical-stage biotechnology company that develops therapeutics...
Phio Pharmaceuticals Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMarlborough, Massachusetts--(Newsfile Corp. - January 15, 2025) - Phio Pharmaceuticals Corp. (
NASDAQ: PHIO), a clinical-stage biotechnology company that develops therapeutics...
Phio Pharmaceuticals Announces $3.19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMarlborough, Massachusetts--(Newsfile Corp. - January 14, 2025) - Phio Pharmaceuticals Corp. (
NASDAQ: PHIO), a clinical-stage biotechnology company that develops therapeutics...
Stocks to Watch in 2025: PHIO, LPTH, KAVL, Promising Innovations, Growth Opportunities, Etc. … more insideAs 2025 kicks off, several companies are standing out as stocks to watch, driven by groundbreaking technologies, strategic market positioning, and strong growth potential. From cutting-edge oncology treatments to defense technology innovations and wellness solutions, these companies are making waves across various sectors. Here's a closer look at stocks like Phio Pharmaceuticals (
NASDAQ: PHIO), LightPath Technologies (
NASDAQ: LPTH), Kaival Brands (
NASDAQ: KAVL), and more, making headlines and capturing investor attention.
Phio Pharmaceuticals Announces Promising Results of Second Cohort from Its Ongoing Clinical Study of PH-762Marlborough, Massachusetts--(Newsfile Corp. - January 13, 2025) - Phio Pharmaceuticals Corp. (
NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics...
Phio Pharmaceuticals Announces Publication in Clinical, Cosmetic and Investigational DermatologyMarlborough, Massachusetts--(Newsfile Corp. - January 2, 2025) - Phio Pharmaceuticals Corp. (
NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics...
Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMarlborough, Massachusetts--(Newsfile Corp. - December 23, 2024) - Phio Pharmaceuticals Corp. (
NASDAQ: PHIO), a clinical-stage biotechnology company that develops therapeutics...
Phio Pharmaceuticals Announces $1.15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMarlborough, Massachusetts--(Newsfile Corp. - December 19, 2024) - Phio Pharmaceuticals Corp. (
NASDAQ: PHIO), a clinical-stage biotechnology company that develops therapeutics...
Phio Pharmaceuticals Announces Publication in Frontiers in ImmunologyMarlborough, Massachusetts--(Newsfile Corp. - December 12, 2024) - Phio Pharmaceuticals Corp. (
NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics...
Phio Pharmaceuticals is a Finalist for the Technology Disruptor of the Year AwardMarlborough, Massachusetts--(Newsfile Corp. - December 10, 2024) - Phio Pharmaceuticals Corp. (
NASDAQ: PHIO),) is a clinical-stage biotechnology company developing therapeutics...
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow SeriesMarlborough, Massachusetts--(Newsfile Corp. - December 3, 2024) - Phio Pharmaceuticals Corp. (
NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics...
Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study--Six sites across the U.S. are now engaged in Phase1b study Marlborough, Massachusetts--(Newsfile Corp. - November 19, 2024) - Phio...
Phio Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business UpdateMarlborough, Massachusetts--(Newsfile Corp. - November 14, 2024) - Phio Pharmaceuticals Corp. (
NASDAQ: PHIO) is a clinical-stage biotechnology company exploring new...
Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)Marlborough, Massachusetts--(Newsfile Corp. - November 7, 2024) - Phio Pharmaceuticals Corp. (
NASDAQ: PHIO) is a clinical-stage biotechnology company creating new...
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow SeriesMarlborough Massachusetts--(Newsfile Corp. - November 1, 2024) - Phio Pharmaceuticals Corp. (
NASDAQ: PHIO) is a clinical-stage biotechnology company creating new...
